These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

259 related articles for article (PubMed ID: 8697306)

  • 1. Progressive deterioration of beta-cell function in nonobese type 2 diabetic subjects. Postprandial plasma C-peptide level is an indication of insulin dependency.
    Prando R; Odetti P; Melga P; Giusti R; Ciuchi E; Cheli V
    Diabetes Metab; 1996 Jun; 22(3):185-91. PubMed ID: 8697306
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Is type 2 diabetes a different disease in obese and nonobese patients?
    Prando R; Cheli V; Melga P; Giusti R; Ciuchi E; Odetti P
    Diabetes Care; 1998 Oct; 21(10):1680-5. PubMed ID: 9773730
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impaired beta-cell and alpha-cell function in African-American children with type 2 diabetes mellitus--"Flatbush diabetes".
    Banerji MA
    J Pediatr Endocrinol Metab; 2002 Apr; 15 Suppl 1():493-501. PubMed ID: 12017222
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Short-term effects of continuous subcutaneous insulin infusion treatment on insulin secretion in non-insulin-dependent overweight patients with poor glycaemic control despite maximal oral anti-diabetic treatment.
    Valensi P; Moura I; Le Magoarou M; Pariès J; Perret G; Attali JR
    Diabetes Metab; 1997 Feb; 23(1):51-7. PubMed ID: 9059766
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Incretin secretion in relation to meal size and body weight in healthy subjects and people with type 1 and type 2 diabetes mellitus.
    Vilsbøll T; Krarup T; Sonne J; Madsbad S; Vølund A; Juul AG; Holst JJ
    J Clin Endocrinol Metab; 2003 Jun; 88(6):2706-13. PubMed ID: 12788877
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [The utility of postprandial C-peptide evaluation in type 2 diabetes].
    Prando R; Giusti R; Ciuchi E; Giusto M; Melga PL; Cheli V
    Riv Eur Sci Med Farmacol; 1996; 18(3):95-104. PubMed ID: 9213846
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Role of standard test meal in initiation of insulin therapy in type 2 diabetes].
    Koprivica B; Beljić-Zivković T; Ille T
    Srp Arh Celok Lek; 2009; 137(9-10):490-6. PubMed ID: 19950754
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of diminished beta cell reserve and insulin resistance in secondary sulfonylurea failure of type 2 diabetes mellitus.
    Rattarasarn C; Thamprasit A; Leelawattana R; Soonthornpun S; Setasuban W
    J Med Assoc Thai; 2001 Dec; 84(12):1754-62. PubMed ID: 11999824
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Glucagon-stimulated and postprandial plasma C-peptide values as measures of insulin secretory capacity.
    Koskinen PJ; Viikari JS; Irjala KM
    Diabetes Care; 1988 Apr; 11(4):318-22. PubMed ID: 3042307
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Beta cell response to oral glimepiride administration during and following a hyperglycaemic clamp in NIDDM patients.
    van der Wal PS; Draeger KE; van Iperen AM; Martini C; Aarsen M; Heine RJ
    Diabet Med; 1997 Jul; 14(7):556-63. PubMed ID: 9223393
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Improved beta-cell function after intensive insulin treatment in severe non-insulin-dependent diabetes.
    Glaser B; Leibovich G; Nesher R; Hartling S; Binder C; Cerasi E
    Acta Endocrinol (Copenh); 1988 Jul; 118(3):365-73. PubMed ID: 3293339
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cellular and humoural autoimmunity markers in type 2 (non-insulin-dependent) diabetic patients with secondary drug failure.
    Zavala AV; Fabiano de Bruno LE; Cardoso AI; Mota AH; Capucchio M; Poskus E; Fainboim L; Basabe JC
    Diabetologia; 1992 Dec; 35(12):1159-64. PubMed ID: 1478368
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characterization of beta-cell function impairment in first-degree relatives of type 2 diabetic subjects: modeling analysis of 24-h triple-meal tests.
    Mari A; Gastaldelli A; Natali A; Ostergard T; Schmitz O; Ferrannini E
    Am J Physiol Endocrinol Metab; 2005 Mar; 288(3):E541-6. PubMed ID: 15522997
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Correlations between fasting plasma C-peptide, glucagon-stimulated plasma C-peptide, and urinary C-peptide in insulin-treated diabetics.
    Gjessing HJ; Matzen LE; Frøland A; Faber OK
    Diabetes Care; 1987; 10(4):487-90. PubMed ID: 3304899
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Simple empirical assessment of beta-cell function by a constant infusion of glucose test in normal and type 2 (non-insulin-dependent) diabetic subjects.
    Levy JC; Rudenski A; Burnett M; Knight R; Matthews DR; Turner RC
    Diabetologia; 1991 Jul; 34(7):488-99. PubMed ID: 1916054
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impaired first-phase insulin response predicts postprandial blood glucose increment in patients with recently diagnosed type 2 diabetes.
    Gredal C; Rosenfalck AM; Dejgaard A; Hilsted J
    Scand J Clin Lab Invest; 2007; 67(3):327-36. PubMed ID: 17454847
    [TBL] [Abstract][Full Text] [Related]  

  • 17. C-peptide response to glucagon in young diabetics.
    Juang JH; Huang BY; Huang HS; Lin JD; Huang MJ
    Taiwan Yi Xue Hui Za Zhi; 1989 Jun; 88(6):579-83. PubMed ID: 2677232
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Beta-cell response to intravenous glucagon in African-American and Hispanic children with type 2 diabetes mellitus.
    Taha DR; Castells S; Umpaichitra V; Bastian W; Banerji MA
    J Pediatr Endocrinol Metab; 2002 Jan; 15(1):59-67. PubMed ID: 11822582
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Glucagon-stimulated insulin secretion in patients with type 2 diabetes mellitus: support for the concept of glucose toxicity.
    Wolffenbuttel BH; Menheere PP; Nijst L; Rondas-Colbers GJ; Sels JP; Nieuwenhuijzen Kruseman AC
    Neth J Med; 1992 Jun; 40(5-6):277-82. PubMed ID: 1436266
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Insulin secretion and immuno-genetic markers in diabetics with 'secondary failure' of oral hypoglycemic agents.
    Colman PG; Harrison LC; Tait BD
    Aust N Z J Med; 1985 Apr; 15(2):209-12. PubMed ID: 3896215
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.